This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Coronary Syndrome or Heart Failure
and you are
between 35 and 75
years old
This is an early phase trial to investigate
how or whether the drug affects your body.
Show me locations

The purpose

Epicardial Infarct Repair with CorMatrix-Extracellular Matrix (ECM) is an open-label, non-randomized, feasibility pilot study. Following ischemic injury the ECM of the heart adversely remodels leading to cardiac fibrosis, left ventricular (LV) dilatation and subsequent heart failure. Preclinical evidence demonstrates that epicardial infarct repair with CorMatrix-ECM restores the damaged ECM, prevents LV dilatation and improves myocardial performance. This study will interrogate epicardial infarct repair in patients undergoing coronary artery bypass grafting (CABG) surgery within 6 weeks following acute myocardial infarction as an adjunct to surgical revascularization. Patients will be evaluated for markers of cardiac function and left ventricular remodelling using cardiac magnetic resonance imaging (MRI). Adverse events will be monitored to ensure safety.

Provided treatments

  • Device: Epicardial Infarct Repair with CorMatrix-ECM
  • Procedure: Coronary Artery Bypass Grafting Surgery

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02887768. The sponsor of the trial is University of Calgary and it is looking for 8 volunteers for the current phase.
Official trial title:
Cardiac Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study